Shuangdan Mingmu Capsule for Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Jiaan Du; Yingqi Mao; Youhua Xu; Kai Qu; Aiwei Han; Qibiao Wu; Lili Yu

doi:10.1155/2023/4655109

Shuangdan Mingmu Capsule for Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Evid Based Complement Alternat Med. 2023 Jan 25:2023:4655109. doi: 10.1155/2023/4655109. eCollection 2023.

Authors

Jiaan Du¹, Yingqi Mao¹, Youhua Xu^{1

2}, Kai Qu³, Aiwei Han¹, Qibiao Wu^{1

2

4

5}, Lili Yu^{1

2}

Affiliations

¹ Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.
² The State Key Laboratory for Quality Research in Chinese Medicines of the Macau University of Science and Technology, Macau 999078, China.
³ Shaanxi Provincial Hospital of Chinese Medicine, Xi'an 710003, China.
⁴ Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangdong University of Technology, Guangzhou, Guangdong, China.
⁵ Zhuhai MUST Science and Technology Research Institute, Zhuhai, Guangdong, China.

Abstract

Objective: To systematically evaluate the efficacy and safety of the Shuangdan Mingmu capsule in the treatment of diabetic retinopathy (DR).

Methods: Common Chinese and English databases, including PubMed, Medline, Embase, VIP, Wanfang, and the Chinese National Knowledge Infrastructure (CNKI), were searched from their inception to May 31, 2022. According to the Cochrane Handbook, two reviewers independently evaluated and collected data on the included studies. Meta-analysis was performed by RevMan software 5.4.

Results: Seven trials with a total of 835 patients were included. The clinical effectiveness rate was defined as the primary outcome, and the TCM symptom score, Chinese-Version Low Vision Quality of Life Questionnaire (CLVQOL) scores, macular thickness, hemorrhagic spot area, vascular endothelial growth factor levels, platelet-derived growth factor levels, and the incidence of adverse effects were the secondary outcome. The results of the meta-analysis showed that, compared with conventional medical treatment alone, the Shuangdan Mingmu capsule combined with conventional treatment could significantly improve the clinical effectiveness rate of treating DR (OR = 4.07, 95% CI (2.10, 7.89), p < 0.0001), and reduce the incidence of adverse reactions in DR patients (OR = 0.47, 95% CI (0.26, 0.86), p=0.01). In addition, other results showed that TCM symptom score(OR = -3.47, 95% CI (-3.84, -3.10), p < 0.00001); CLVQOL scores (OR = 23.93, 95% CI (21.37, 26.49), p < 0.00001); macular thickness (OR = -47.34, 95% CI (-50.67, 44.00), p < 0.00001); hemorrhagic spot area (OR = -0.91, 95% CI (-1.01, -0.81), p < 0.00001); vascular endothelial growth factor levels (OR = -45.76, 95% CI (-49.74, 41.79), p < 0.00001); platelet-derived growth factor levels (OR = -1.73, 95% CI (-2.15, -1.31), p < 0.00001).

Conclusion: Compared with conventional treatment alone, the Shuangdan Mingmu capsule combined with conventional treatment is more effective and safer in the treatment of diabetic retinopathy. However, due to the limitations of the included studies, more high-quality studies are still needed to further assess the efficacy and safety of the Shuangdan Mingmu capsule in the treatment of diabetic retinopathy.

Publication types

Review